Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)

Metabolic Syndrome Clinical Trial

Official title:

Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01911078
• Other study ID #: CI-12-079-EU-RD
• Status: Completed
• Phase: N/A
• Start date: September 2014
• Est. completion date: June 2016

Study information

• Verified date: January 2019
• Source: Abbott Medical Devices
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical investigation is to determine the effects of renal sympathetic denervation on insulin resistance and muscle sympathetic nerve activity in patients with metabolic syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patient with office blood pressure =140/90 mmHg and 24-hour ambulatory blood pressure =130/80 mmHg at Baseline despite the stable use of at least two anti-hypertensive drugs at maximum tolerated doses of the patient for at least 4 weeks

• Patient with a fasting glucose =100 mg/dL (=5.6 mmol/L) at Baseline or on drug treatment for elevated glucose

• Patient with a waist circumference =102 cm (=40 inches) for male or =88 cm (=35 inches) for female at Baseline

• Patient with any of the remaining two metabolic syndrome diagnostic criteria listed as follows at Baseline

• Triglycerides =150 mg/dL (=1.7 mmol/L) or on drug treatment for elevated triglycerides

• High density lipid cholesterol (HDL-C) <40 mg/dL (<1.03 mmol/L) for male or <50 mg/dL (<1.30 mmol/L) for female or on drug treatment for reduced HDL-C

• Patient is =18 and =70 years old

• Patient must be able and willing to provide written informed consent to participate in this clinical investigation

• Patient must be able and willing to comply with the required follow-up schedule

Exclusion Criteria:

• Patient with secondary hypertension

• Patient with type I diabetes mellitus or type II diabetes mellitus requiring insulin therapy

• Patient with prior renal angioplasty, renal denervation, indwelling renal stents and/or aortic stent grafts

• Patient with renal arteries <4.0 mm in diameter

• Patient with significant renovascular abnormalities (such as renal artery stenosis >30%)

• Patient with an estimated glomerular filtration rate (eGFR) of <45 mL/min per 1.73 m2 using the Modified Diet in Renal Disease (MDRD) formula

• Patient with hemodynamically significant valvular heart disease, as determined by Study Investigator

• Patient has had a myocardial infarction, unstable angina pectoris or cerebrovascular accident less than 180 days at Baseline or is expected to have cardiovascular intervention within the next 180 days

• Patient is in chronic atrial fibrillation/flutter or with severe conduction abnormalities or with an implantable cardioverter defibrillator (ICD) or pacemaker whose settings cannot allow for radiofrequency (RF) energy delivery

• Patient is currently being treated with drugs that cause salt retention (such as systemic corticosteroids or fludrocortisone), centrally acting sympatholytic antihypertensive drugs, direct vasodilators (such as alpha blockers) and continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea

• Patient with an active systemic infection or blood-clotting abnormalities or allergy to radiographic contrast

• Patient is pregnant or of childbearing potential and is not using adequate contraceptive methods or nursing

• Patient is participating in another clinical investigation

• Patient has a life expectancy less than 12 months, as determined by Study Investigator

Related Conditions & MeSH terms

• Metabolic Syndrome
• Metabolic Syndrome X
• Syndrome

Intervention

Procedure:
• Renal Denervation
Renal artery ablation with the EnligHTN™ Renal Denervation System.

Device:
• EnligHTN™ Renal Denervation System.

Locations

Country	Name	City	State
Greece	Hippocration Hospital, University of Athens	Athens

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in insulin resistance from baseline to 3 months after renal denervation	To determine the effects of renal sympathetic denervation on insulin resistance (determined by the Homeostasis Model Assessment - Insulin Resistance method) at 3 months after renal denervation	Baseline and Month 3
Primary	Change in muscle sympathetic nerve activity (MSNA) from baseline to 3 months after renal denervation	To determine the effects of renal sympathetic denervation on MSNA at 3 months after renal denervation	Baseline and Month 3
Secondary	Change in insulin resistance from baseline to 12 months after renal denervation	To determine the effects of renal sympathetic denervation on insulin resistance long-term (12 months after renal denervation).	Baseline and Month 12
Secondary	Change in muscle sympathetic nerve activity (MSNA) from baseline to 12 months after renal denervation	To determine the effects of renal sympathetic denervation on MSNA long-term (12 months after renal denervation).	Baseline and Month 12